Core Viewpoint - Innovent Biologics has successfully included seven innovative products in the updated 2025 National Reimbursement Drug List (NRDL), enhancing patient access to critical therapies for major diseases in China [1][2]. Product Summaries - TYVYT® (sintilimab injection): Newly included indication for advanced endometrial cancer in combination with fruquintinib, addressing a significant treatment gap for patients with limited responses to traditional therapies [4][3]. - SYCUME® (teprotumumab N01 injection): First approved IGF-1R antibody drug in China, newly listed for moderate-to-severe thyroid eye disease, significantly improving patient accessibility and affordability [6][5]. - Limertinib: Newly listed for treating advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC) and as a first-line treatment for specific EGFR mutations, offering enhanced penetration across the blood-brain barrier [9][8]. - Dupert® (fulzerasib): Newly listed for advanced NSCLC patients with KRAS G12C mutation, providing a novel targeted therapy option [10]. - DOVBLERON® (taletrectinib): Newly listed for locally advanced or metastatic ROS1-positive NSCLC, potentially offering a best-in-class therapy [12][11]. - Retsevmo® (selpercatinib): Newly listed for various indications in NSCLC and thyroid cancer, being the first RET inhibitor approved globally [14][13]. - Jaypirca® (pirtobrutinib): Newly listed for relapsed or refractory mantle cell lymphoma, addressing unmet needs for heavily treated patients [16][15]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing affordable, high-quality medicines for oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases [17]. The company has launched 17 products and has multiple assets in various stages of clinical trials [17].
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List